OnKure Therapeutics Reports Q3 GAAP EPS of -$0.36 and Strong Cash Runway
OnKure Therapeutics (OKUR) has reported its third-quarter financial results, posting a GAAP earnings per share (EPS) of -$0.36. Despite the quarterly loss, the company maintains a robust liquidity position with $163.3 million in cash, cash equivalents, and marketable securities as of September 30, 2024. The company's current strategic focus is on advancing its next-generation PI3Kα pan-mutant-selective candidates. Specifically, OnKure is executing IND-enabling activities for OKI-345, targeting breast cancer, and OKI-355, targeting vascular anomalies, with plans to submit Investigational New Drug (IND) applications in the first half of 2027.
Coverage
- Bicara Therapeutics GAAP EPS of -$1.04 misses by $0.22
- Aura Biosciences Reports Q3 GAAP EPS of -$0.29 and Strong Cash Position
- Tango Therapeutics Reports Q3 2026 GAAP EPS of -$0.39
- NI Holdings Reports Q3 Earnings with Positive EPS Turnaround
- Phio Pharmaceuticals GAAP EPS of -$0.36 in-line
- vTv Therapeutics GAAP EPS of -$0.94 beats by $0.15
- OnKure Therapeutics Reports Q3 GAAP EPS of -$0.36 and Strong Cash Runway